Tuesday 21 May 2019 ,
Tuesday 21 May 2019 ,
Latest News
  • Tunisia boat capsize: 15 survivors return home
  • NZ mosque attacker charged with terrorism
  • US delays Huawei ban for 90 days
  • Ramadan, Iftar evoke feelings of nostalgia among Rohingyas
  • OC withdrawn over Rajshahi schoolgirl’s suicide after rape
13 May, 2019 00:00 00 AM

New lesions ID'd on breast MRI during treatment likely benign

HealthDay
New lesions ID'd on breast MRI during treatment likely benign

For patients undergoing neoadjuvant chemotherapy for locally advanced breast cancer, magnetic resonance imaging (MRI) examinations with new suspicious findings are unlikely to represent a new site of malignancy, according to a study presented at the annual meeting of the American Roentgen Ray Society, held from May 5 to 10 in Honolulu.

Donna Eckstein, M.D., from the University of California in San Francisco, and colleagues identified all breast MRI examinations performed to assess response to neoadjuvant chemotherapy from 2000 to 2018. Study cases classified as Breast Imaging Reporting and Data System (BI-RADS) 4 or 5 were identified. All cases with new suspicious lesions found after initiation of neoadjuvant treatment were included; 28 MRI examinations were included.

The researchers found that all study cases were identified as BI-RADS 4. Sixteen lesions were contralateral to known malignancy, while 11 and one were ipsilateral and bilateral, respectively. Lesions included mass, nonmass enhancement, and focus (18, eight, and two, respectively).

Twenty-five of the cases had tissue diagnosis or sufficient imaging follow-up to establish diagnosis; the outcomes were unknown in three cases. In cases with known outcomes, none of the new suspicious findings were malignant, while 11, five, and nine were proven benign at percutaneous biopsy, proven benign at surgical pathology, and presumed benign after resolution of the suspicious lesions or stability over more than two years, respectively.

"Our findings suggest that new suspicious findings on MRI arising during neoadjuvant therapy are almost certainly benign, although larger studies across facilities are needed to confirm whether biopsy may be safely averted in these scenarios," the authors write.

 

Comments

Most Viewed
Digital Edition
More story
From the Editor

From the Editor

Irritable Bowel Syndrome or IBS is a disorder characterised most commonly by cramping, abdominal pain, bloating, constipation and diarrhea. IBS causes…
FAQ on Irritable Bowel Syndrome

FAQ on Irritable Bowel Syndrome

IBS affects between 25 and 45 million Americans. Most of them are women. People are most likely to get the condition in their late teens to early 40s.…
Irritable bowel syndrome (IBS): a long-term gastrointestinal disorder

Irritable bowel syndrome (IBS): a long-term gastrointestinal disorder

CHRISTIAN NORDQVIST Irritable bowel syndrome, or irritable bowel disease, is a long-term gastrointestinal disorder. It causes abdominal pain, bloating,…
Coping with IBS

Coping with IBS

Coping with irritable bowel syndrome (IBS) presents a number of daily challenges. While there is no cure for the disorder, treatments are available. Learn…
12 Foods to avoid with IBS

12 Foods to avoid with IBS

A healthy diet generally consists of eating a wide variety of nutritious foods in moderation. If you have irritable bowel syndrome (IBS), you may notice…
Bowel movement disorders

Bowel movement disorders

Bowel (intestinal) function varies greatly not only from one person to another but also for any one person at different times. It can be affected by diet,…
Type 2 diabetes: losing even a small amount of weight may lower heart disease risk

Type 2 diabetes: losing even a small amount of weight may lower heart disease risk

People with type 2 diabetes are often encouraged to lose weight. And recent studies have shown that losing a lot of weight can reverse diabetes, meaning…
Autism estimates for the USA are wildly inaccurate, say experts at INSAR 2019

Autism estimates for the USA are wildly inaccurate, say experts at INSAR 2019

SALLY ROBERTSON The Centers for Disease Control and Prevention (CDC) has released new statistics on autism. They estimate that there has been a 15% increase…
Biochemical compound responsible for blood pressure drop in sepsis

Biochemical compound responsible for blood pressure drop in sepsis

MARIA FERNANDA ZIEGLER International research group demonstrates the involvement of singlet molecular oxygen in vasodilation, causing a sharp decline…
icddr,b launches artificial intelligence based  diabetic retinopathy detection

icddr,b launches artificial intelligence based diabetic retinopathy detection

Recently, icddr,b in collaboration with Eyes For All PLC, United Arab Emirates and DIAGNOS Inc, Canada have launched an artificial intelligence (AI) based…
Hospitals to test mums-to-be for risky group-B strep

Hospitals to test mums-to-be for risky group-B strep

Screening for a life-threatening bacterial infection affecting newborn babies is to be offered at 80 hospitals in England, Wales and Scotland. About 150,000…
FDA approves Dengvaxia (dengue vaccine) for the prevention of dengue disease in endemic regions

FDA approves Dengvaxia (dengue vaccine) for the prevention of dengue disease in endemic regions

The U.S. Food and Drug Administration announced recently the approval of Dengvaxia, the first vaccine approved for the prevention of dengue disease caused…

Copyright © All right reserved.

Editor : M. Shamsur Rahman

Published by the Editor on behalf of Independent Publications Limited at Media Printers, 446/H, Tejgaon I/A, Dhaka-1215.
Editorial, News & Commercial Offices : Beximco Media Complex, 149-150 Tejgaon I/A, Dhaka-1208, Bangladesh. GPO Box No. 934, Dhaka-1000.

Editor : M. Shamsur Rahman
Published by the Editor on behalf of Independent Publications Limited at Media Printers, 446/H, Tejgaon I/A, Dhaka-1215.
Editorial, News & Commercial Offices : Beximco Media Complex, 149-150 Tejgaon I/A, Dhaka-1208, Bangladesh. GPO Box No. 934, Dhaka-1000.

Disclaimer & Privacy Policy
....................................................
About Us
....................................................
Contact Us
....................................................
Advertisement
....................................................
Subscription

Powered by : Frog Hosting